Oropharyngeal Cancer Archives - Cancer Therapy Advisor

A T-cell therapy that targets a protein only expressed on HPV-positive cancers has shown low toxicity and impressive responses in some patients enrolled in a phase 1/2 clinical trial.

Head and Neck Cancer

Short-Term Mortality Risks Appear Higher in HPV-Negative Oropharyngeal Cancer

By

Leah Lawrence

January 30, 2020

This study assessed causes of early mortality stratified by HPV status in oropharynx cancer.

Head and Neck Cancer

Toxicity Similar, But Overall Survival Poor in Cetuximab vs Cisplatin for HPV-Positive Oropharyngeal Cancer

By

Tiffany Garbutt, PhD

November 26, 2019

In a randomized phase 3 trial, researchers sought to determine if cetuximab-based chemoradiotherapy could be a less-toxic alternative to cisplatin-based chemoradiotherapy in patients with HPV-positive oropharyngeal cancer.

Head and Neck Cancer

Incidence of HPV-Positive OPSCC Is Double That Seen in HPV-Negative Disease

By

Leah Lawrence

August 8, 2019

Incidence was greatest among white men aged 60 to 64 years.

In mice, DNA-encoded plasmids generated sufficient in vivo expression of immune checkpoint antibody

Head and Neck Cancer

Gene Signature Predicts Outcomes in HPV-Related Oropharyngeal Cancers

By

Christina Bennett, MS

February 1, 2019

HPV gene signature was associated with outcomes in patients with HPV-related oropharyngeal cancers and could become a prognostic biomarker.

Oropharyngeal cancers have become the most common HPV-associated malignancies in the US, where the r

Head and Neck Cancer

As HPV-Related Cancer Rates Climb, Experts Scrutinize Barriers to HPV Vaccination

By

Bryant Furlow

October 11, 2018

Oropharyngeal cancers have become the most common HPV-associated malignancies in the US, where the rate of vaccination against HPV lags compared with other countries.

Patients with locally advanced or metastatic renal cell carcinoma randomly assigned to receive pazop

Head and Neck Cancer

Phase 1b/2 Study of DPX-E7 + Cyclophosphamide in HPV-positive Cancers

By

Cancer Therapy Advisor Staff

April 11, 2017

Researchers are evaluating whether DPX-E7 vaccination is safe and will improve outcomes among patients with HPV-positive head and neck, cervical, or anal cancer.

The American Society of Clinical Oncology (ASCO) named Immunotherapy 2.0 the “advance of the year.”

Head and Neck Cancer

Phase 2 Study of ADXS 11-001 Vaccination in HPV-positive Oropharyngeal Squamous Cell Carcinoma

By

Cancer Therapy Advisor Staff

April 11, 2017

Researchers are evaluating whether ADXS 11-001 vaccination prior to transoral surgery will improve outcomes for patients with HPV-positive oropharyngeal cancer.

HPV Update: Increased Incidence of Throat Cancer

Head and Neck Cancer

TORS May Improve Swallowing Function in Patients With Oropharyngeal Cancer

By

Jason Hoffman, PharmD, RPh

July 5, 2016

Findings suggest that TORS is a promising strategy for improving swallowing function in patients with OPSCC, without compromising disease-free survival.

The confluence of the basket study design and genomic sequencing is speeding delivery of targeted tr

General Oncology

New Staging System for HPV-positive Oropharyngeal Cancer Proposed

By

Lourdes Briz

February 29, 2016

The ICON-S developed a TNM classification specific to human papillomavirus (HPV)-related oropharyngeal cancer.

Head and Neck Cancer

HPV-16 in Oral Cavity Associated With Increased Risk of Oropharyngeal Squamous Cell Carcinoma

By

John Schieszer, MA

January 28, 2016

Detection of human papillomavirus (HPV)-16 in the oral cavity may be associated with 22-times increased risk of oropharyngeal squamous cell carcinoma.